NASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis $1.66 -0.01 (-0.30%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$1.72 +0.07 (+3.92%) As of 09:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About X4 Pharmaceuticals Stock (NASDAQ:XFOR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get X4 Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.63▼$1.7950-Day Range$1.66▼$4.3052-Week Range$1.63▼$26.96Volume594,569 shsAverage Volume138,028 shsMarket Capitalization$9.61 millionP/E Ratio0.77Dividend YieldN/APrice Target$72.33Consensus RatingBuy Company Overview X4 Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule modulators of G protein-coupled receptors (GPCRs). The company’s research emphasizes the SDF-1/CXCR4 axis and other GPCR targets to regulate cell trafficking and immune response. X4’s technology platform is designed to address unmet needs in oncology, immunology and rare diseases by selectively modulating receptor activity. The lead candidate in X4’s pipeline, X4P-001, is being developed as a therapeutic agent to mobilize hematopoietic stem cells for transplantation and to enhance immune-oncology regimens. Additional programs include X4P-202, a selective sphingosine-1-phosphate receptor modulator with potential applications in pulmonary arterial hypertension and autoimmune disorders, and X4P-003, targeting rare immunological diseases. These programs are advancing through preclinical and early clinical stages with a goal of demonstrating safety and efficacy in well‐defined patient populations. Founded as a spin-out from GlycoMimetics in 2020 and headquartered in Cambridge, Massachusetts, X4 Pharmaceuticals leverages both in‐house expertise and external collaborations to accelerate development. The company maintains research activities in the United States and Europe and has established partnerships with academic institutions and contract research organizations to support its preclinical and clinical efforts. Under the leadership of President and Chief Executive Officer Monee C. McGrath, X4 Pharmaceuticals has assembled a management team with deep experience in drug discovery, clinical development and regulatory affairs. The company’s strategic focus on novel GPCR modulators positions it to deliver differentiated therapies aimed at improving outcomes for patients with serious and underserved diseases.AI Generated. May Contain Errors. Read More X4 Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreXFOR MarketRank™: X4 Pharmaceuticals scored higher than 93% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingX4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about X4 Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.68) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is 0.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.91.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is 0.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.00.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about X4 Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.63% of the float of X4 Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in X4 Pharmaceuticals has recently increased by 22.15%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.85 Percentage of Shares Shorted12.63% of the float of X4 Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in X4 Pharmaceuticals has recently increased by 22.15%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,559.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.37% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about X4 Pharmaceuticals' insider trading history. Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XFOR Stock News HeadlinesX4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 0.3% - Should You Sell?July 10 at 2:23 AM | americanbankingnews.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comWhy Volatility Keeps Coming Back — And How I Trade ItVolatility isn’t the enemy — it’s the opportunity. While most traders panic during market swings, Jeff Clark uses a three-step method to target quick wins from VIX spikes and sudden price moves. It works in any market direction… and he’s showing how it works in a free video, available now.July 10 at 2:00 AM | TradeSmith (Ad)X4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comSee More Headlines XFOR Stock Analysis - Frequently Asked Questions How have XFOR shares performed this year? X4 Pharmaceuticals' stock was trading at $22.0080 on January 1st, 2025. Since then, XFOR shares have decreased by 92.5% and is now trading at $1.66. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) released its quarterly earnings results on Thursday, May, 1st. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($4.13) by $4.17. The business earned $28.81 million during the quarter, compared to analyst estimates of $7.03 million. X4 Pharmaceuticals had a negative trailing twelve-month return on equity of 181.56% and a net margin of 46.54%. Read the conference call transcript. When did X4 Pharmaceuticals' stock split? X4 Pharmaceuticals shares reverse split on the morning of Monday, April 28th 2025.The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Intel (INTC). Company Calendar Last Earnings5/01/2025Today7/09/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XFOR CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for X4 Pharmaceuticals$72.33 High Price Target$120.00 Low Price Target$7.00 Potential Upside/Downside+4,257.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$2.14 Trailing P/E Ratio0.77 Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.45 million Net Margins46.54% Pretax Margin47.58% Return on Equity-181.56% Return on Assets-54.36% Debt Debt-to-Equity Ratio3.30 Current Ratio3.70 Quick Ratio3.58 Sales & Book Value Annual Sales$2.56 million Price / Sales3.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book0.43Miscellaneous Outstanding Shares5,790,000Free Float5,652,000Market Cap$9.61 million OptionableOptionable Beta0.54 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:XFOR) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.